LY3938577 for Type 2 Diabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new drug, LY3938577, to see if it is safe for healthy people and those with Type 2 Diabetes. The study will check how well people tolerate the drug over several weeks.
Will I have to stop taking my current medications?
If you are taking sulfonylurea, thiazolidinedione, alpha-glucosidase inhibitor, glucagon-like peptide-1 receptor agonist, or insulin, you must stop these medications at least 3 months before joining the trial.
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
This trial is for healthy adults and those with Type 2 Diabetes Mellitus (T2DM). Healthy participants should have a BMI of 18.5-32 kg/m², while T2DM participants can have up to 40 kg/m². T2DM should be diagnosed over a year ago. People with severe eye or nerve complications, recent steroid therapy, or participation in another study recently cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Part A
Participants receive a single dose of LY3938577 or placebo in healthy participants and participants with Type 2 Diabetes Mellitus
Treatment Part B
Participants with Type 2 Diabetes Mellitus receive multiple doses of LY3938577
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- LY3938577
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University